Release Date: 30-Aug-2023
Columvi is another cancer therapeutic developed by Genentech (Roche). The drug was the first bispecific antibody to be approved for the treatment of diffuse large B-cell lymphoma. It was initially approved by Health Canada and then by the US FDA. Columvi is now also approved in the EU; nevertheless, it is currently only available for clinical use in the US, where it was approved in June 2023. As the sole market for Columvi at present, the US produced drug revenues of CHF 5 million (US$ 5.7 million) in the second quarter of 2023. Columvi sales are likely to increase once the drug enters the EU market, which happens to be Roche’s second largest market.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028